🏛️ Verified NIH Record • Updated 2025-10-29
SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST (NCT06208748)
A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST Who Progressed on Sunitinib Monotherapy
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Sarcoma Alliance for Research through Collaboration
🩺 Plain-English Summary (8th-Grade Level)
This is an open label, single arm, phase 2 trial investigating bezuclastinib plus sunitinib in patients with GIST who have previously progressed on sunitinib.
Who can join: Review the eligibility criteria below.
Location: Sylvester Comprehensive Cancer Center, University of Miami — Miami, Florida
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- Sylvester Comprehensive Cancer Center, University of Miami — Miami, Florida
- Dana Farber Cancer Institute — Boston, Massachusetts
- Oregon Health & Science University — Portland, Oregon
- Fox Chase Cancer Center — Philadelphia, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Gastrointestinal Stromal Tumors
- A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib — Scottsdale, Arizona
- Phase 2 Study to Evaluate the Efficacy of Regorafenib in Specific GIST Mutation Subsets (KIT Exon 17, 18, or 14 Mutation and SDHB Deficient GIST) in the Post-imatinib Second-line Setting. — Houston, Texas
- ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST — Miami, Florida
- Preoperative Imatinib and Fampridine in KIT Mutant Gastrointestinal Stromal Tumor — La Jolla, California
- Imatinib TDM in GIST — Lexington, Kentucky
Explore by condition: All Gastrointestinal Stromal Tumors clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.